

**Daito's Authorized Generic of  
Wilson's Disease Treatment "NOBELZIN®" (copper absorption inhibitor)  
Receives Additional Indication Approval**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo/Managing Director & CEO: Jin Shiomura) announced that its licensee, Daito Pharmaceutical Co., Ltd. (Headquarters: Toyama-shi, Toyama/President and CEO: Yasunobu Otsuga), received the approval for the additional indication of zinc acetate tablets 25 mg/50 mg "Nobel" (the "Product"), the authorized generic ("AG") of its Wilson's disease treatment "NOBELZIN®" tablets 25 mg/50 mg (copper absorption inhibitor) as follows:

The active and inactive ingredients, the manufacturing method and the manufacturer of this Product are the same as those of NOBELZIN®. Daito filed the approval application and has just received the approval for the hypozincemia in addition to the already approved indication of Wilson's disease (hepatolenticular degeneration).

Nobelpharma and Daito cooperate in the drug information services of this Product under the marketing alliance.

Nobelpharma continues carrying out its duty for NOBELZIN® tablets and granule as an original drug manufacturer based on the accumulated treatment outcomes including the drug information services.

Daito Pharmaceutical Co., Ltd.

Daito constantly strives to contribute to the healthy life and growth of people and stably supply high-quality pharmaceutical products by cultivating the skills focused on development and manufacturing. Of all others, it contributes to the reduction in healthcare costs of the nation and the patients by supplying generic drugs at reasonable prices.

Nobelpharma is determined to keep on contributing to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for Inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

phone: 03-6670-3800